Antibody drug conjugate ILUMYA (tildrakizumab-asmn) treatment of moderate-severe plaqueized psoriasis: good long-term safety effectiveness

The pharmaceutical company Sun today announced that it will present the long-term use and cost-benefit analysis of ILUMYATM (tildrakizumab-asmn, targeting IL-23) for the treatment of moderate to severe plaqueps at the 2020 American Society of Dermatology (AAD) virtual meetingA long-term analysis of reSURFACE 1 and 2 extended studies found that ILUMYA provided consistent and improved results for patients with moderate to severe plaque psoriasis who received up to four years of treatment without finding new safety risksIn addition, the safety of ILUMYA was confirmed in a five-year analysis that showed a lower incidence of malignant tumors from the fourth to the fifth yearMost malignancies are a single event, with a similar incidence to the general population in the United StatesAn after-the-fact analysis of 335 patients with moderate to severe plaque psoriasis found that patients who reached PASI 50 or higher after 6 months of iLUMYA treatment continued to improve and their response rate increased for up to three yearsThose who reached PASI-90 at the 28th week were improved rapidly as early as week 4